Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Dermatologic 1Breast 1

Conditions

Melanoma 2Head and Neck Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 24Nivolumab 9atezolizumab 8Drug Therapy 6cemiplimab 5Immune Checkpoint Inhibitors 5fludarabine 4Radiotherapy 4Paclitaxel 4Interleukin-2 4Cyclophosphamide 4Docetaxel 3fludarabine phosphate 2epacadostat 2durvalumab 2aldesleukin 2Taxes 2Radiosurgery 2Radiation 2Patient Reported Outcome Measures 2Oncolytic Virotherapy 2Ipilimumab 2Immunotherapy 2Gemcitabine 2Filgrastim 2Cisplatin 2Cetuximab 2Carboplatin 2vocimagene amiretrorepvec 1venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Sonazoid × Dermatologic × Clear all
NCT07310758 2025-12-30

Contrast-enhanced Ultrasound for Sentinel Node Detection

The Netherlands Cancer Institute

Phase 2/3 Recruiting
91 enrolled
BreastDermatologicHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡